Erratum to: Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer

被引：0
|
作者：
Johanna C. Bendell
Lee S. Rosen
Robert J. Mayer
Jonathan W. Goldman
Jeffrey R. Infante
Fabio Benedetti
Donghu Lin
Hirokazu Mizuguchi
Christopher Zergebel
Manish R. Patel
机构：
[1] Sarah Cannon Research Institute/Tennessee Oncology,
[2] PLLC,undefined
[3] University of California,undefined
[4] Dana-Farber Cancer Institute,undefined
[5] Taiho Oncology Inc.,undefined
[6] Taiho Pharmaceutical of Beijing Co.,undefined
[7] Ltd.,undefined
[8] Sarah Cannon Research Institute/Florida Cancer Specialists,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2016年 / 77卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：439 / 439
相关论文
共 50 条
  • [1] Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer
    Johanna C. Bendell
    Lee S. Rosen
    Robert J. Mayer
    Jonathan W. Goldman
    Jeffrey R. Infante
    Fabio Benedetti
    Donghu Lin
    Hirokazu Mizuguchi
    Christopher Zergebel
    Manish R. Patel
    [J]. Cancer Chemotherapy and Pharmacology, 2015, 76 : 925 - 932
  • [2] Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer
    Bendell, Johanna C.
    Rosen, Lee S.
    Mayer, Robert J.
    Goldman, Jonathan W.
    Infante, Jeffrey R.
    Benedetti, Fabio
    Lin, Donghu
    Mizuguchi, Hirokazu
    Zergebel, Christopher
    Patel, Manish R.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (05) : 925 - 932
  • [3] TAS-102 for metastatic refractory colorectal cancer
    Cleghorn, Sean
    [J]. LANCET ONCOLOGY, 2015, 16 (07): : E314 - E314
  • [4] Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer (vol 76, pg 925, 2015)
    Bendell, Johanna C.
    Rosen, Lee S.
    Mayer, Robert J.
    Goldman, Jonathan W.
    Infante, Jeffrey R.
    Benedetti, Fabio
    Lin, Donghu
    Mizuguchi, Hirokazu
    Zergebel, Christopher
    Patel, Manish R.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (02) : 439 - 439
  • [5] A phase 1b expansion study of TAS-102 with oxaliplatin for refractory metastatic colorectal cancer
    Cecchini, Michael
    Kortmansky, Jeremy S.
    Cui, Can
    Wei, Wei
    Thumar, Jaykumar Ranchobdhai
    Uboha, Nataliya, V
    Hafez, Navid
    Lacy, Jill
    Fischbach, Neal A.
    Sabbath, Kert D.
    Gomez, Christina M.
    Sporn, Jonathan Reed
    Stein, Stacey
    Hochster, Howard S.
    [J]. CANCER, 2021, 127 (09): : 1417 - 1424
  • [6] Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
    Mayer, Robert J.
    Van Cutsem, Eric
    Falcone, Alfredo
    Yoshino, Takayuki
    Garcia-Carbonero, Rocio
    Mizunuma, Nobuyuki
    Yamazaki, Kentaro
    Shimada, Yasuhiro
    Tabernero, Josep
    Komatsu, Yoshito
    Sobrero, Alberto
    Boucher, Eveline
    Peeters, Marc
    Tran, Ben
    Lenz, Heinz-Josef
    Zaniboni, Alberto
    Hochster, Howard
    Cleary, James M.
    Prenen, Hans
    Benedetti, Fabio
    Mizuguchi, Hirokazu
    Makris, Lukas
    Ito, Masanobu
    Ohtsu, Atsushi
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (20): : 1909 - 1919
  • [7] TAS-102 in metastatic colorectal cancer
    Burki, Talha Khan
    [J]. LANCET ONCOLOGY, 2018, 19 (01): : E18 - E18
  • [8] Tas-102 for Refractory Metastatic Colorectal Cancer: A Multicenter Retrospective Cohort Study
    Conti, Matteo
    Bolzacchini, Elena
    Luchena, Giovanna
    Bertu', Lorenza
    Tagliabue, Paola
    Aglione, Stefania
    Ardizzoia, Antonio
    Arnoffi, Jessica
    Guida, Francesco Maria
    Bertolini, Alessandro
    Pastorini, Alessandro
    Duro, Maria
    Bettega, Donato
    Roda', Giovambattista
    Artale, Salvatore
    Squizzato, Alessandro
    Giordano, Monica
    [J]. CANCERS, 2023, 15 (13)
  • [9] Treatment of TAS-102 in patients with metastatic colorectal cancer
    Ota, Takayo
    Tsukuda, Hiroshi
    Hasegawa, Yoshikazu
    Miyatake, Nozomi
    Suzumura, Tomohiro
    Fukuoka, Masahiro
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [10] A phase I study of TAS-102 in combination with oxaliplatin (TAS-OX) for refractory metastatic colorectal cancer (mCRC).
    Cecchini, Michael
    Kortmansky, Jeremy S.
    Lacy, Jill
    Fischbach, Neal A.
    Thumar, Jaykumar Ranchodbhai
    Sabbath, Kert D.
    Gomez, Christina M.
    Sporn, Jonathan
    Stein, Stacey
    Hochster, Howard S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
12345